Skip To Main Content
Vibha Ravi on Muck Rack

Vibha Ravi

Verified
Mumbai
As seen in: Citeline, Scrip, The Pink Sheet, Moneycontrol, In Vivo, Generics Bulletin
Senior Editor - Scrip, Pink Sheet. Tweets on pharma, health, environment, other topics of interest to those who read beyond headlines, social media
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vibha

Contact Vibha, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Europe May Follow France’s Biosimilar Lead, Germany Reforms Cut Both Ways: Lupin CEO

|
By Vibha Ravi Verified
| Generics Bulletin Verified
France’s model of incentivizing biosimilars substitution to aid innovator drug purchases could be worthy of emulation while Germany’s recently announced changes cut both ways, says Lupin’s CEO Vinita Gupta as she also talks of South Africa semaglutide launch plans.
Open in Who Shared Issue with article?

Aurobindo Claims 5-7 Year Headstart With A1 Biochem, Lannett Acquisitions

|
By Vibha Ravi Verified
| Generics Bulletin Verified
US Generic Advair Launch In August The acquisition of US-based Lannett and India’s A1 Biochem, that has a US lab, have helped Aurobindo Pharma leapfrog onshoring and R&D capability scale-ups by five to seven years, giving it the confidence to handle mandatory US onshoring if required. (Shutterstock) Competitive advantage is the name of the game when it comes to acquisitions.
Open in Who Shared Issue with article?

Zydus Deal Drops Mereo BioPharma A Lifeline For Rare Disease Candidate Alvelestat

|
By Vibha Ravi Verified
| Scrip Verified
Setrusumab Update By End-2026, Vantictumab Advancing To Phase II A deal between Zydus subsidiary Sentynl and UK biotech Mereo BioPharma will help alvelestat, an investigational oral drug to treat AATD-LD, progress to global Phase III trials in early 2027. Meanwhile, Mereo expects an update on setrusumab by end-2026.
Open in Who Shared Issue with article?
See all 587 articles